TSO

TriSourceObserve

Slow journalism for technology, industry, and capital.

Stories

Capital Flow

Shows how policy, balance sheets, market structure, and investor expectations transmit change across industries.

AllMacro InsightsCorporate StrategyFinTech & Future AssetsSector Deep-dive
TSO / High confidence
Capital FlowCorporate Strategy

Victoria’s Secret Faces Proxy Fight Ahead of Shareholders Meeting as Director Mariam Naficy Will Not Seek Re-Election

Victoria’s Secret disclosed ahead of its annual shareholders meeting that director Mariam Naficy will not seek re-election, while the company’s proxy fight with activist investor BBRC chairman Brett Blundy over board seats is intensifying. Confirmed information shows BBRC owns 13% of the company and has asked shareholders to vote “withhold” on board chair Donna James and Naficy. The company has also publicly laid out reasons for opposing Blundy’s entry to the board, but the details and background of those allegations vary across the three sources.

May 14, 2026
Read analysis
TSO / High confidence
Capital FlowMacro Insights

U.S. April CPI Rises to 3.8% and Core CPI to 2.8%, with Three Sources Consistently Pointing to Rising Inflation

All three sources confirm that U.S. April CPI rose 3.8% year over year and core CPI increased to 2.8%, interpreting the data as a rebound in inflationary pressure from previous levels. Reuters and CNBC both note that the reading came in above market expectations, while Yahoo Finance highlights energy prices as one of the main drivers. On the Federal Reserve’s next steps, all three sources point in the direction of keeping rates unchanged for longer, but any claim that the Fed may “reassess further rate hikes” is a media inference and cannot be directly confirmed from the provided sources.

May 14, 2026
Read analysis
TSO / High confidence
Capital FlowSector Deep-dive

Isomorphic Labs Completes $210 Million Series B Financing, Led by Thrive Capital

Alphabet-backed AI biotech company Isomorphic Labs announced the completion of a Series B financing round worth about $210 million. Cross-source verification confirms that Thrive Capital led the round, with participation from Alphabet/GV, Temasek, CapitalG, and the U.K. AI Fund/UK Sovereign AI Fund. The use of proceeds points to the expansion of its AI drug-design platform, but the claim that the funds will also advance internal programs into clinical trials appears only in the event summary and cannot be confirmed from the sources provided.

May 13, 2026
Read analysis
TSO / High confidence
Capital FlowCorporate Strategy

European Mid-Sized Pharma Firms Rapidly Acquire U.S. Biopharma Assets: Is a Cross-Border M&A Wave Underway?

From late April to early May, three European mid-sized pharmaceutical companies made successive moves in the U.S. biopharma sector: Chiesi acquired KalVista, Angelini bought Catalyst for about $4.1 billion, and Leo Pharma acquired Replay. The three sources point to a series of consecutive deals within the same time window, but they do not provide enough information to confirm whether this amounts to a “systematic buying trend” or to fully verify every deal term.

May 13, 2026
Read analysis
TSO / High confidence
Capital FlowSector Deep-dive

Cushman & Wakefield Forecasts AI Could Lift U.S. Industrial, Office, and Retail Property Demand by About 12% Over the Next Decade

Based on a baseline scenario, Cushman & Wakefield projects that AI will increase demand for U.S. industrial, office, and retail space by about 12% over the next 10 years, or roughly 330 million square feet. The core conclusion is confirmed by three sources, which also indicate the forecast is built on a multi-scenario framework and that the office market is likely to become more polarized, with demand favoring high-quality, adaptable space. Details on AI adoption timing, exact outcomes under different scenarios, and differentiated impacts across property types were not fully disclosed in the provided sources.

May 12, 2026
Read analysis
TSO / High confidence
Capital FlowCorporate Strategy

Cerebras Raises US IPO Price Range and Offering Size, with Three Sources Pointing to Stronger Demand

Cross-checked against Reuters, Bloomberg, and The Motley Fool, Cerebras Systems raised its US IPO price range to $150 to $160 per share in May 2026 and increased the number of shares on offer to 30 million. The three sources agree on the core terms, though they differ slightly in the timing of disclosure, wording, and how the fundraising amount is presented.

May 12, 2026
Read analysis